Fletikumab  (Synonyms: NNC 0109-0012)

Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

IL-20

Fletikumab blocks IL-20 binding IL-20 receptor, acts potential function of inflammation inhibition^[1].
IL-20 is a member of IL-10 family, which includes IL-10, IL-19, IL-22, IL-24, IL-26, IL-28, and IL-29. IL-20 acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

50604  [NCBI]

Q9NYY1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.48 kDa

1357158-22-5

Liquid

Colorless to light yellow

[Fletikumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Kragstrup TW, et al. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Front Immunol. 2018 Sep 25;9:2226.   [Content Brief]

  [2]. Tian-Yu Lin, et al. IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target. Int. J. Mol. Sci. 2020, 21(3), 1009.  [Content Brief]